Medical Device Innovation Consortium (MDIC)’s Post

How could a 9️⃣9️⃣.9️⃣9️⃣% reduction in bacterial adhesion on your vascular access catheters improve your patient outcomes? The data presented at the Association for Vascular Access Annual Meeting in 2023 and the Infusion Nurses Society Annual Meeting in 2024 strongly supports MIMIX®️ technology in achieving this goal. We invite you to explore this compelling evidence and our multiple clinical studies. Please reach out at https://loom.ly/ElpFRfM *While in vitro data is valuable, it doesn’t always predict clinical outcomes. #vascularaccess #datadriven #patientoutcomes

When patients present to the emergency department (ED), 70% require a peripheral intravenous catheter (PIVC). A quarter of these patients have difficult intravenous access, with half needing multiple attempts for successful placement. This can lead to venous depletion, patient dissatisfaction, treatment delays, and increased costs. In a randomised controlled trial funded by EMF, Dr Grace Xu compared the insertion success and device failure of a novel long PIVC with a retractable coiled guidewire (GW-PIVC), to standard care PIVC. Analysing data from 446 participants, the study found that standard PIVC had a better insertion rate, higher patient satisfaction, and lower costs than GW-PIVC. Dr Xu's research highlighted the need for further studies to address complex insertion techniques and training gaps. Dr Xu was part of another study into PIVC insertion, which identified insufficient training as a key barrier to following the PIVC clinical care standard, negatively impacting success and patient satisfaction. EMF Funded LOVE-DIVA Study: https://lnkd.in/eqDSfbMY Authors: Hui (Grace) Xu, Amanda Corley, Emily R. Young, Anna Doubrovsky, Robert S. Ware, Clifford Afoakwah, Carrie Wang, Scott Stirling, Nicole Marsh For more information and publications: - Complementary Qualitative LOVE-DIVA Study: https://lnkd.in/eRFAFGyS - PIVC related studies: https://lnkd.in/esVDiEsD https://lnkd.in/eDUAq6Kz https://lnkd.in/e8t3yvCR #EMFResearch #EmergencyMedicineResearch #MedicalResearch #PIVCResearch

Insights from Dr. Steven McCarus, COO of AIMIS - Endometriosis is a chronic disease burdening both individuals and society. Its complexity, compounded by overlapping symptoms and contributors, often leads to delays in diagnosis and treatment. In a recent study, Dr. McCarus and his team synthesized current research and clinical practices to develop a clinical algorithm aimed at reducing symptoms, shortening time to diagnosis, and improving patient outcomes. Key findings: Early evaluation using best clinical practices can expedite diagnosis and intervention, leading to better management of the disease. Modulating estradiol levels through medical therapy offers noninvasive pain relief for endometriosis symptoms. Detailed patient history, examination, and pain diaries are essential for determining the appropriate course of action. Structured follow-up and shared decision-making between clinicians and patients are crucial for achieving optimal outcomes. Surgical intervention, when strategically combined with medical therapy, can yield more predictable and longer-lasting results. By implementing these strategies, we can work towards improving the lives of individuals affected by endometriosis. Let's continue advancing research and clinical practices to alleviate the burden of this challenging condition. #Edometriosis #CaseStudy #Study #InnovationInSurgery #AIMISJourney #EndometriosisAwareness #MedicalResearch #PatientCare #Awareness

The comprehensive Positive Quality Intervention (PQI) on the utilization of nirogacestat in the management of adults with progressing desmoid tumors (or fibromatosis/aggressive fibromatosis) provides insight into the initiation and management protocols for adult patients. Highlighting the latest guidelines, this precise and concise clinical guidance resource outlines the dosage forms now available, including: 50 mg (180-count bottle) 100 mg (14-count blister pack) 150 mg (14-count blister pack) tablets Stay informed and elevate your clinical practices with this invaluable resource tailored for optimal patient care. https://bit.ly/3ulJvXa

NEW MANUSCRIPT: The management of patient with melanocytic lesions is dependent on the diagnosis with guidelines defining treatment protocols for benign nevi and malignant melanomas. Even though diagnostic discordance and diagnostic ambiguity have been previously established, the real-world impact on patient management is not well understood. Using an exhaustive review process by multiple dermatopathologists and a simulated patient treatment model, this study reveals that diagnostic discordance and ambiguity may be more common that previously reported and identifies significant variation in patient treatment in these lesions. Read the full manuscript here: https://hubs.la/Q02yZtK00

🆕 The World Health Organization has unveiled a groundbreaking online platform called #MeDevIS (Medical Devices Information System). This comprehensive database includes 2,301 medical devices, spanning various treatments and diagnoses such as neonatal care, cancer, cardiovascular disease, and diabetes. This new database will serve as a valuable source for industry professionals, regulatory agencies and healthcare providers and researchers. It is the first database of its kind, and was modeled based on WHO experience managing their Priority Medical Devices List (#MDL). MEDEVIS will be continuously expanded to other health technologies, for additional health conditions and diseases. Follow us for regulatory updates and scientific insights! 💻www.toxhub-consulting.com 📩 info@toxhub-consulting.com #ToxHub #Toxicity #Consultancy #MedicalDevices #MDR

https://lnkd.in/gHmQRUa9 How do we define RV dysfunction and injury in patients with ARDS? Fairly dense article here without a whole lot of clinical relevance but certainly something that will carry forward into subsequent study designs and discussions.

Is Myocardial Infarction Overdiagnosed? Up to 20% Misdiagnoses The risk of overdiagnosing MI appears to be higher than underdiagnosing it. Some studies have estimated a 9% diagnostic error rate in patients clinically suspected of having an MI. In certain clinical trials, these diagnostic errors were found to be as high as 15%-20% after secondary analysis and strict application of MI definitions. A Universal Definition of Myocardial Infarction? This is what payers are using to clinically validate MI. Physicians must use their clinical judgment, applying the Universal Definition of MI, and describe, tell, and show the patient's clinical story with signs/symptoms of cardiac ischemia to correlate with other clinical tests to support the diagnosis of MI. Payers are focusing on NSTEMIs/Type II MI and throwing out the diagnosis left right and center. CDIS's role is to ensure proper documentation that supports the MI, providing feedback in the event of denials and promoting complete and accurate documentation in the first place. Remember, it is far better to educate physicians on documentation practices than queryrate. #CDI, #MI, #praoactive, #reactive, #doingright, #denialsavodiance, #overdiagnosisofMI, #misdiagnosis https://lnkd.in/dvnkHGFY

How can #patientpreferences shape the future of #clinicaltrials? Discover the latest Executive Summary from the SPI Heart Failure (HF) Working Group of MDIC. This study underscores the importance of incorporating patient input into trial designs and offers insight into the risk-benefit trade-off for HF patients. Dive into the research and discover how it can lead to more patient-centered health technologies: https://lnkd.in/etmKkjsm

Beta-Blockers Yield No Benefit After Myocardial Infarction in Patients with Normal LVEF 08 Apr, 2024 • In acute MI patients who underwent early coronary angiography and had a preserved left ventricular ejection fraction (≥50%), long-term beta-blocker therapy showed no significant benefit. • A large study published in the New England Journal of Medicine found no significant difference in the primary composite endpoint of death from any cause or new Ml between the beta-blocker and non-beta-blocker groups (7.9% vs. 8.3%; HR 0.96). • Safety endpoints also demonstrated comparable rates of adverse events, suggesting no clear benefit from beta-blocker therapy in this patient population. Read fullstory https://lnkd.in/dQ5sZYBj